A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2) - A.R.R.O.W.2

Amgen Inc0 sites460 target enrollmentStarted: June 11, 2020Last updated: October 26, 2021

Drugs

Trial Snapshot

Phase: Phase 1
Status: Active, not recruiting
Sponsor: Amgen Inc
Enrollment: 460

Study Overview Eligibility Criteria Investigators Records & Identifiers Similar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type: Interventional clinical trial of medicinal product

Eligibility Criteria

Sex: All

Inclusion Criteria

•*Subject has provided informed consent prior to initiation of any study-specific activities or procedures or subject’s legally acceptable representative has provided informed consent prior to any study-specific activities/procedures being initiated when the subject has any kind of condition that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent.
•*Males or females = 18 years of age.
•*Documented relapse or progressive multiple myeloma after last treatment Subjects refractory to the most recent line of therapy are eligible, unless last treatment contained PI or lenalidomide and dexamethasone).
•*Subjects must have at least PR to at least 1 line of prior therapy.
•*Subjects must have received at least 1 but not more than 3 prior lines of therapy for multiple myeloma (induction therapy followed by stem cell transplant and consolidation maintenance therapy will be considered as 1 line of therapy). See Section 12.8 for guidelines for documenting prior treatment.
•* Prior therapy with a PI is allowed if the patient achieved at least a PR to the most recent therapy with a PI, did not relapse within 60 days of discontinuation, and PI was not removed due to toxicity
•* Prior therapy with a lenalidomide and dexamethasone is allowed if the patient achieved at least a PR to the most recent therapy with lenalidomide and dexamethasone, did not progress within 3 months of a lenalidomide and dexamethasone-containing treatment, did not relapse within 60 days of discontinuation of treatment, and treatment was not removed due to toxicity
•History of prior neuropathy is permitted if this was not grade 3, grade 4 or grade 2 with pain and if not resolved within the 14 days before enrollment, is less than or equal to grade 2 without pain
•Patients are permitted to have received single agent lenalidomide as maintenance therapy within 60 days of enrollment
•* Measurable disease with at least 1 of the following assessed within 28 days prior to randomization:
•IgG multiple myeloma: serum monoclonal protein (M-protein) level = 1.0 g/dL
•IgA, IgD, IgE multiple myeloma: serum M-protein level = 0.5 g/dL
•urine M-protein = 200 mg per 24 hours
•in subjects without measurable serum or urine M-protein, serum-free light chain (SFLC) = 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio
•*Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 = 2 (see Section 12.9).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 230
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 230

Exclusion Criteria

•Disease-related
•*Waldenström macroglobulinemia.
•*Multiple myeloma of IgM subtype.
•*POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
•*Plasma cell leukemia (> 2.0 × 109/L circulating plasma cells by standard differential).
•*Primary amyloidosis (patients with multiple myeloma with asymptomatic deposition of amyloid plaques found on biopsy would be eligible if all other criteria are met).
•*Myelodysplastic syndrome.
•Other Medical Conditions
•*History of other malignancy within the past 5 years, with the following exceptions:
•Malignancy treated with curative intent and with no known active disease present for = 3 years before enrollment and felt to be at low risk for recurrence by the treating physician
•Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
•Adequately treated cervical carcinoma in situ without evidence of disease
•Adequately treated breast ductal carcinoma in situ without evidence of disease
•Prostatic intraepithelial neoplasia without evidence of prostate cancer
•Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ
•Treated medullary or papillary thyroid cancer
•Similar neoplastic conditions with an expectation of > 95% 5-year disease-free survival
•* Known HIV infection, hepatitis C infection (subjects with hepatitis C that achieve a sustained virologic response after antiviral therapy are allowed), or hepatitis B infection (subjects with hepatitis B surface antigen or core antibody that achieve sustained virologic response with antiviral therapy are permitted with a requirement for regular monitoring for reactivation for the duration of treatment on the study).
•*Ongoing graft-vs-host disease.
•*Acute active infection requiring systemic antibiotics, antifungal, antiviral (except antiviral therapy directed at hepatitis B) agents within 14 days prior to randomization.
•*Known cirrhosis.
•*Significant neuropathy (grades 3 to 4, or grade 2 with pain) within 14 days prior to randomization.
•*Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization. Cardiopulmonary Conditions
•* Uncontrolled hypertension, defined as subject whose blood pressure exceeds = 160 mmHG - systolic or = 100mmHg diastolic when taken in accordance with the European Society of hypertensions/European Society of cardiology 2018 guidelines. (Section 12.10; Williams et al, 2018).
•*Active congestive heart failure (New York Heart Association Class III to IV), symptomatic ischemia, uncontrolled arrhythmias, screening ECG with corrected QT interval (QTc) of > 470 msec, pericardial disease, or myocardial infarction within 4 months prior to randomization.
•*Intolerance to hydration due to pre-existing pulmonary or cardiac impairment.
•*History of interstitial lung disease or ongoing interstitial lung disease.
•Prior/Concomitant Therapy
•*Immunotherapy within 28 days prior to randomization.
•*Monoclonal antibody therapy within 28 days prior to randomization.
•*Chemotherapy with approved anticancer therapeutic within 28 days prior to randomization.
•*Glucocorticoid therapy within 14 days prior to randomization that exceeds a cumulative dose of 160 mg of dexamethasone or equivalent dose of other corticosteroids.
•*Focal radiation therapy within 7 days prior to randomization. Radiation therapy to an extended field involving a significant volume of bone marrow within 28 days prior to rando

Investigators

Sponsor

Amgen Inc

Similar Trials

Active, not recruiting

Phase 1

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864

EUCTR2018-000665-36-ATAmgen Inc460

Active, not recruiting

Phase 1

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

EUCTR2018-000665-36-FRAmgen Inc460

Active, not recruiting

Phase 1

EUCTR2018-000665-36-BGAmgen Inc460

Active, not recruiting

Phase 1

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the treatment of Patients With Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaMedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864

EUCTR2016-003554-33-BGAmgen Inc450

Completed

Phase 3

A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2)

NL-OMON52761Amgen2